Australia markets close in 1 minute

Cellectar Biosciences, Inc. (CLRB)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.0700-0.1700 (-5.25%)
At close: 04:00PM EDT
3.0799 +0.01 (+0.32%)
After hours: 07:15PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 110.06M
Enterprise value 107.10M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.67
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.99
52-week change 3122.46%
S&P500 52-week change 326.27%
52-week high 34.4500
52-week low 31.3600
50-day moving average 33.5532
200-day moving average 32.8451

Share statistics

Avg vol (3-month) 3977.09k
Avg vol (10-day) 3650.05k
Shares outstanding 535.85M
Implied shares outstanding 635.85M
Float 824.21M
% held by insiders 13.56%
% held by institutions 128.96%
Shares short (30 Apr 2024) 42.55M
Short ratio (30 Apr 2024) 42.83
Short % of float (30 Apr 2024) 48.06%
Short % of shares outstanding (30 Apr 2024) 47.10%
Shares short (prior month 28 Mar 2024) 42.53M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 317 July 2018
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 322 July 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-144.66%
Return on equity (ttm)-536.81%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -38.77M
Net income avi to common (ttm)-37.98M
Diluted EPS (ttm)-3.1100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)9.56M
Total cash per share (mrq)0.3
Total debt (mrq)552.98k
Total debt/equity (mrq)N/A
Current ratio (mrq)0.81
Book value per share (mrq)-0.36

Cash flow statement

Operating cash flow (ttm)-32.38M
Levered free cash flow (ttm)-15.44M